Richard Kollender

Richard S.
Kollender is Chief Executive Officer & Director at Reaction Biology Corp.
since 2024.
He is Chairman at Restorative Therapies, Inc. since 2018.
He serves as Independent Director at Rapid Micro Biosystems, Inc. since 2018.
He is Director at Cortendo AB since 2015.
He is Director at Tarsa Therapeutics, Inc. He is Director at Ocugenix Corp.
since 2019.
He is a Member of The American Institute of Certified Public Accountants.
He is Partner at Quaker Partners Management LP since 2003.
He is a Member of the Pennsylvania Institute of Certified Public Accountants.
He is Vice President at Quaker BioVentures Management LLC.
He is Partner at Quaker BioVentures Management LP since 2003.
He is Vice President at Quaker BioVentures Capital II LLC.
Formerly, he was Chairman at TargetRx, Inc. He was Independent Director at Insmed, Inc. from 2011 to 2013.
He was Director at Corcept Therapeutics, Inc. He was Director at Transport Pharmaceuticals, Inc. He was Independent Director at Jazz Pharmaceuticals Therapeutics, Inc. from 2013 to 2016.
He was Independent Director at NuPathe, Inc. from 2012 to 2014.
He was Director at Medmark, Inc. He was Director at GlaxoSmithKline, Inc. He was Director at Transave, Inc. He was Director at Helomics Corp.
He was Director at Axe Compute, Inc. He was Director at Corridor Pharmaceuticals, Inc. He was Director at Greater Philadelphia Alliance for Capital & Technologies.
He was Accountant at KPMG LLP.
He was Investment Manager at GSK Equity Investments Ltd. He was President & Chief Financial Officer at Strongbridge Biopharma Plc from 2021 to 2022.
Education includes an MBA from The University of Chicago and undergraduate studies at Franklin & Marshall College.